Solid Biosciences Inc.
SLDB
$2.70
$0.031.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 96.43M | -- | -- | -- | 76.56M |
| Gross Profit | -96.43M | -- | -- | -- | -76.56M |
| SG&A Expenses | 9.13M | 7.86M | 8.33M | 7.99M | 6.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.90M | 35.18M | 27.79M | 26.86M | 22.27M |
| Operating Income | -39.90M | -35.18M | -27.79M | -26.86M | -22.27M |
| Income Before Tax | -42.60M | -32.73M | -25.07M | -24.30M | -20.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.60M | -32.73M | -25.07M | -24.30M | -20.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.60M | -32.73M | -25.07M | -24.30M | -20.34M |
| EBIT | -39.90M | -35.18M | -27.79M | -26.86M | -22.27M |
| EBITDA | -39.41M | -34.78M | -26.55M | -26.54M | -22.05M |
| EPS Basic | -1.00 | -0.79 | -0.61 | -0.64 | -1.01 |
| Normalized Basic EPS | -0.62 | -0.49 | -0.38 | -0.40 | -0.63 |
| EPS Diluted | -1.00 | -0.79 | -0.61 | -0.64 | -1.01 |
| Normalized Diluted EPS | -0.62 | -0.49 | -0.38 | -0.40 | -0.63 |
| Average Basic Shares Outstanding | 42.71M | 41.44M | 40.93M | 38.16M | 20.23M |
| Average Diluted Shares Outstanding | 42.71M | 41.44M | 40.93M | 38.16M | 20.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
